Surveillance Imaging Protocol for NHL Post-Chemotherapy
For patients with non-Hodgkin lymphoma in complete remission after curative-intent chemotherapy, routine surveillance imaging with CT or PET/CT is NOT recommended; instead, perform clinical follow-up with history and physical examination every 3-6 months for the first 2 years, then annually, with imaging reserved only for clinically suspected relapse.
Evidence-Based Rationale
The strongest guideline evidence comes from ESMO 1, which explicitly states that routine surveillance with PET scan is not recommended [V, E], and that minimal radiological examinations at 6,12, and 24 months by CT scan are common practice but lack definitive evidence of outcome advantage. The NCCN guidelines 2 similarly note that "imaging should be performed whenever there are clinical indications" rather than routinely.
Recommended Surveillance Protocol
Clinical Follow-Up Schedule
- Years 1-2: Every 3 months with history, physical examination, and blood counts 1
- Years 3-5: Every 6 months 1
- After 5 years: Annually 2, 1
Laboratory Monitoring
- Complete blood count at 3,6,12, and 24 months
- Thereafter only as needed for suspicious symptoms or clinical findings 1
When to Image
Image only when clinically indicated, specifically:
- New or worsening symptoms reported by patient
- Abnormal physical examination findings
- Unexplained laboratory abnormalities
- Rising LDH levels (though LDH alone is not sensitive for relapse 3)
Why Routine Imaging Is Not Recommended
Multiple high-quality studies demonstrate that surveillance imaging provides no survival benefit:
Detection method doesn't affect survival: The largest study 4 of 163 NHL patients showed 77.9% of relapses were detected by symptoms/exam versus 22.1% by surveillance imaging (P<.0001), with no overall survival difference between groups (P=.66)
High false-positive rates: Surveillance PET/CT yields false positives in 25-42% of scans 5, leading to unnecessary biopsies, additional testing, and patient anxiety
No survival advantage: Multiple studies 6, 3, 4 consistently show that detecting asymptomatic relapse through surveillance imaging does not improve overall survival or post-relapse survival
Significant radiation exposure: Current surveillance protocols expose 44% of patients to cumulative radiation doses that double their risk of secondary malignancies 7
High cost, low yield: Surveillance PET/CT accounts for >75% of follow-up healthcare costs in the first 2 years, with an estimated cost of $50,000 per relapse detected 4, 5
Important Subtype Considerations
Aggressive B-Cell Lymphoma (DLBCL)
- Strongest evidence against routine imaging 1, 8
- Patients event-free at 2 years have survival identical to general population 1
- Positive predictive value of surveillance PET is particularly low in low-risk patients 8
Indolent B-Cell Lymphoma (Follicular)
- Surveillance imaging may detect deep lesions (mesenteric/retroperitoneal) earlier 9
- However, this does not translate to survival benefit 9
- Clinical follow-up remains the standard 2
Aggressive T-Cell NHL
- May have higher positive predictive value (>60%) for surveillance PET 8
- Consider more frequent clinical evaluation in high-risk patients 1
Critical Clinical Pitfalls
Watch for signs of histologic transformation (particularly in follicular lymphoma):
- Disproportionate growth of single site
- Rising LDH levels
- New extranodal disease
- New B symptoms
- In these cases, FDG-PET may help identify biopsy targets, but biopsy is mandatory before changing treatment 2
Always biopsy suspicious findings before initiating salvage therapy 1, as false positives are common and secondary malignancies can occur.
High-Risk Exception
For select high-risk patients with curative salvage options, more frequent clinical evaluation may be warranted 1, but this still emphasizes clinical assessment over routine imaging.